Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 1, 2001

View Archived Issues

Infliximab effective against plaque-type psoriasis

Enzyme replacement shown effective in Fabry's disease

Meta-analysis shows HRT reduces nonvertebral fractures, especially in younger women

Thalidomide improves survival in multiple myeloma patients

Antigenics significantly expands product portfolio during Q2 2001

Esperion Therapeutics updates clinical trial programs

BioErgonomics and Loma Linda enter agreement to develop AD diagnostic

Results reported from phase II OvaRex ovarian cancer trial

Amarin and Elan announce partnership to establish Parkinson's franchise

Sanguine's synthetic red blood cell product shows good stability

Microcide and Althexis sign merger agreement

British Biotech broadens product portfolio during past year

Kos Pharmaceuticals receives approvable letter for niacin/lovastatin tablets

Peregrine and Oakwood Labs to develop tumor necrosis therapy using anticancer liposome technology

GPI-1046 protects nigral neurons in mice

Novartis's TCH-346 is neuroprotective against MPTP toxicity in monkeys

Bico acquires rights for several rapid HIV diagnostic tests

Lead compounds discovered in collaboration between Otsuka and Pharmacopeia

New advanced tool for protein identification will aid in rapid drug target identification

AstraZeneca patents new insulin-sensitizing agents

Novel series of aminopropylphosphinic acid derivatives described by AstraZeneca

Compounds with neurotrophic and neuroprotective activity disclosed by Bristol-Myers Squibb

New derivatives for reversing drug-induced neuromuscular block presented by Azko Nobel

Ono Pharmaceutical describes new chemokine receptor antagonists

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...